Mistral Pharma Inc.
TSX VENTURE : MIP

Mistral Pharma Inc.

November 01, 2007 07:53 ET

Mistral Pharma Launches INSTILLAGEL® on the Canadian Market

First 3 in 1 sterile gel indicated for anaesthesia, lubrication and antisepsis during urology procedures

MONTREAL, QUEBEC--(Marketwire - Nov. 1, 2007) - Mistral Pharma Inc. (TSX VENTURE:MIP) ("Mistral") today announced that it is launching INSTILLAGEL® on the Canadian market. INSTILLAGEL® is now available to all urology clinics, hospitals and pharmacies across Canada. INSTILLAGEL® is a sterile gel containing lidocaine 2% and chlorhexidine 0,05% and is indicated for surface anaesthesia, lubrication and antisepsis for the male and female urethra during cytoscopy, catheterization, exploration by sound and other endourethral operations.

"We are very proud to launch our first product in Canada" commented Bertrand Bolduc, Mistral's President & CEO. "Mistral now has its own sales force, which will offer INSTILLAGEL® to the medical community. We know that many urologists are looking forward to trying the product in order to make urology procedures go more smoothly for patients" he added.

"It is with great pleasure that we are bringing INSTILLAGEL® to Canadian urologists" said Dalal Manoli, Mistral's Vice President, Sales and Marketing. INSTILLAGEL® is already available in 34 countries and has been used more than 350 million times in over 30 years. We are convinced that Canadian urologists will really like this product, which makes urology procedures very smooth for both doctors and patients.

About Mistral Pharma Inc.

Mistral Pharma Inc. is an innovative pharmaceutical company that is active in the reformulation and the commercialization of already-marketed drugs. Its branded drug delivery products, MIST-B01, MIST-B02 & MIST-B03, showed positive results at their respective first pilot clinical trials. Mistral also markets INSTILLAGEL® in Canada, a local anesthetic and antiseptic combination product used for urology procedures. Mistral has also in-licensed TAMALIS™ (Rupatadine) a new antihistamine which should be filed with Health Canada in 2008. Mistral positions itself as a development and marketing partner for pharmaceutical companies. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com.

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on Management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, results from clinical studies and regulatory approval process as well as general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release

Contact Information